Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy-Teva profit sharing for Lipitor generic: just plan B or a three-way pattern?

This article was originally published in Scrip

Executive Summary

Was Ranbaxy's profit-sharing deal with Teva Pharmaceutical Industries for generic Lipitor (atorvastatin) simply part of a fall-back strategy to ensure a day one launch in the US, or is it part of a gameplan modelled along the lines on Ranbaxy's strategy to monetise 180-day exclusivity of generic Flomax (tamsulosin), when it failed to get launch approval on time?

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC015450

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel